JD Health International Inc. disclosed on 16 June 2026 that it has continued to execute its share-repurchase programme, lifting the total number of shares bought for cancellation but not yet cancelled to 18.44 million since 15 May 2026. The aggregate volume equals 0.58 % of the company’s issued share capital at the time the buyback mandate was approved.

The most recent transaction, completed on 16 June, involved 0.50 million shares repurchased on the Hong Kong Stock Exchange at prices between HK$36.18 and HK$36.62, for a total consideration of HK$18.25 million.

Despite the ongoing buybacks, JD Health’s issued share capital remained unchanged at 3.21 billion shares as of the close on 16 June 2026; all repurchased shares are awaiting formal cancellation.

Under the mandate granted on 20 June 2025, the company is authorised to repurchase up to 320.01 million shares. Following the 18.44 million shares already repurchased, capacity for a further 301.57 million shares remains.

JD Health is subject to a 30-day moratorium on issuing new shares or selling any treasury shares, extending through 16 July 2026, in line with Main Board Rule 10.06(3)(a).